Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC.
Rasul
Kakil Ibrahim
KI
Al Amal Cancer Center, Doha, Qatar. dkerr@sidra.org
Kerr
David J
DJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D000068818:Cetuximab; D002945:Cisplatin / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016016:Proportional Hazards Models; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D000068818:Cetuximab; D002945:Cisplatin; D000077235:Vinorelbine
J Clin Oncol. 2005 Sep 1;23(25):5900-9
16043828
J Clin Oncol. 2007 Apr 20;25(12):1545-52
17442998
J Clin Oncol. 2004 Mar 1;22(5):785-94
14990633
N Engl J Med. 2005 Jul 14;353(2):133-44
16014883
Lancet. 2009 May 2;373(9674):1525-31
19410716
Ann Oncol. 2008 Feb;19(2):362-9
17947225
N Engl J Med. 2009 Apr 2;360(14):1408-17
19339720